Lexington Recieves Approval to Commence Clinical Study

Lexington Biosciences (CSE:LNB) a development-stage medical device company, is pleased to announce its recent application for Institutional Review Board approval of its pilot clinical study at Diablo Clinical Research has been approved.
As quoted in the press release:

Lexington’s President Eric Willis comments, “The rapid approval of our clinical study submission speaks volumes to our team’s diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself.  We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead.”

Click here to read the full press release.